Shield Therapeutics plc (LON:STX – Get Free Report)’s share price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 6.18 and traded as low as GBX 5.60. Shield Therapeutics shares last traded at GBX 5.71, with a volume of 3,651,834 shares.
Shield Therapeutics Trading Down 2.6%
The company has a debt-to-equity ratio of -199.87, a current ratio of 0.90 and a quick ratio of 2.16. The stock has a market capitalization of £60.43 million, a price-to-earnings ratio of -2.83 and a beta of 1.76. The business has a 50 day simple moving average of GBX 6.14 and a 200-day simple moving average of GBX 8.07.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Read More
- Five stocks we like better than Shield Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
